Sava Technologies Secures €32.08 Million Series B to Advance Next-Generation Glucose Microsensor in Europe
London‑based health‑tech startup Sava Technologies secured a €32.08 million Series B round led by Ascensia, bringing its next‑generation glucose microsensor closer to European market launch. The funding will be used to scale manufacturing and prepare for commercial rollout, while the partnership with Ascensia provides distribution and commercialization expertise across Europe.